Home・Aandelen Lijst・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Open

SectorGezondheidszorg

19.03 -2.11

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.58

Max

19.64

Belangrijke statistieken
By Trading Economics
Inkomsten	25M -43M
Verkoop	-3.6M 65M
EPS	-0.48
Winstmarge	-65.788
Werknemers	298
EBITDA	-16M -31M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+98.51% upside

Dividenden
By Acuity
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-34M 1.8B
Vorige openingsprijs	21.14
Vorige sluitingsprijs	19.03

Nieuwssentiment

By Acuity

43%

57%

148 / 340 Rangschikking in Healthcare

Syndax Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 jul 2026, 17:06 UTC

Syndax Pharmaceuticals shares are higher as the broader market recovers, with the S&P 500 advancing following recent volatility in U.S. Treasury yields.

29 jul 2026, 19:56 UTC

Macro Event

Syndax Pharmaceuticals Inc shares are lower, continuing a trend with six consecutive daily declines amid broader market concerns over rising crude oil prices.

28 jul 2026, 20:51 UTC

Syndax Pharmaceuticals Inc is trading lower in after-market hours, continuing a six-session decline amid market focus on the Federal Reserve's interest rate decision.

27 jul 2026, 20:06 UTC

Syndax Pharmaceuticals shares are lower as the broader market declines amid falling oil prices, impacting Treasury yields and investor sentiment.

24 jul 2026, 19:52 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a downward trend over the past few days amid broader market pressures.

22 jul 2026, 19:06 UTC

Syndax Pharmaceuticals Inc shares are lower today with no specific news identified. Broader market sentiment is impacted by rising crude oil prices and geopolitical tensions.

Peer Vergelijking

Prijswijziging

Syndax Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

98.51% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 38.67 USD 98.51%

Hoogste 57 USD

Laagste 29 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Syndax Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Syndax Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

148 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.